

Solvency and Financial Condition Report

Sasol International Insurance DAC

sasol
reaching new frontiers



Report Dated 30th June 2023

Table of Contents

Summary	1
A. Business Performance: Year Ended 30th June 2023	2
A.1 General Information about the Business.....	2
A.2 Underwriting Performance	3
A.3 Financial Performance	5
A.4 Investment Performance	6
A.5 Any Other Information	6
B. Systems of Governance	7
B.1 General Information	7
B.2 Fit and Proper Requirements	12
B.3 Risk Management System	13
B.4 Internal Control System.....	20
B.5 Outsourcing	22
B.6 Any Other Information	22
C. Risk Profile	23
C.1 Underwriting Risk	23
C.2 Market Risk	24
C.3 Credit Risk.....	24
C.4 Liquidity Risk	24
C.5 Operational Risk.....	25
C.6 Other Material Risks.....	25
C.7 Any Other Information	25
D. Valuation for Solvency Purposes.....	26
D.1 Assets.....	26
D.2 Technical Provisions	28
D.3 Other Liabilities	31
D.4 Alternative methods for valuation.....	32
D.5 Any other Information	32
E. Capital Management	33
E.1 Own Funds	33
E.2 Solvency Capital Requirement & Minimum Capital Requirement.....	34
E.3 Use of duration based equity risk Sub module in Solvency Capital Requirement calculation.....	37
E.4 Internal Model Information	37
E.5 Non Compliance with Minimum Capital Requirement and Solvency Capital Requirement during the period.....	37
E.6 Any Other Information	38

This page is intentionally blank

Summary

This Solvency and Financial Condition Report (“SFCR”) has been drafted in line with articles 290 through 299 of the Commission Delegation Regulation (EU) 2015/35 of 10 October 2014.

The objective of this report is to consolidate all material and key information relating to Sasol International Insurance DAC (‘SIIDAC’ or ‘the Company’) over the reporting period of 1 July 2022 through 30 June 2023, in respect of the following categories:

- Business and performance
- System of governance
- Risk profile
- Valuation for solvency purposes
- Capital management

The following summarises the information and findings in the subsequent sections of this report:

- The Company’s business remained unchanged from the prior year with no adjustments to the lines of business licensed to be underwritten. The Company achieved a net profit after tax of US\$ 24,450,180 (2022: US\$ 18,666,635). The improvement is primarily due to an increase of US\$16.5M in investment returns compared to FY22 which was however counteracted by a negative swing in net claims incurred of US\$11.5M attributable to a significant loss incurred on the Property Damage and Business Interruption line of business.
- The Company’s System of Governance is robust and fit for purpose with the appointed Board of Directors together with the respective Heads of Functions, adequately fulfilling their requirements over the reporting period.
- The risk profile of the Company has remained unchanged from the prior year with all insurance coverage being provided to Group entities. There were some changes to the levels of risk and retention including an increase to the participations in the excess PDBI layer.
- The Company has calculated its solvency capital requirement (“SCR”) using the standard formula. As at 30 June 2023 the Company’s gross technical provisions as calculated under Solvency II valuation principles were US\$ 71.17M (2022: US\$ 39.98M) compared to GAAP technical provisions of US\$ 68.00M (2022: US\$ 38.27M), as booked in the audited financial statements.
- With eligible capital of US\$ 250.59M (2022: US\$ 225.59M) in place, the Company achieved SCR coverage of 242.2% (2022: 182.1%) and Minimum Capital Requirement (“MCR”) coverage of 968.1% (2022: 727.1%) as at 30 June 2023.

A. Business Performance: Year Ended 30th June 2023

This Solvency and Financial Condition Report ('SFCR') has been prepared to allow Sasol International Insurance DAC ('SIIDAC' or 'the Company') to comply with the Pillar III reporting requirements under Directive 2009/138/EC and associated Regulations ('the Solvency II Directive')

The Company has set a target Solvency Capital Requirement (SCR) cover ratio of 150% (2022: 150%).

A.1 General Information about the Business

Legal Form

The Company was licensed in Ireland on 25th July 2002 and is a wholly owned subsidiary of Sasol Investment Company (Pty) Limited which in turn is a wholly owned subsidiary of Sasol Limited. The Company is authorised by the Central Bank of Ireland (CBI) to carry on the business of insurance in accordance with the regulations as defined in European Union (Insurance and Reinsurance) Regulations 2015 (S.I. 485 of 2015).

Shareholder

Sasol Investment Company (Pty) Limited which is a wholly owned subsidiary of Sasol Limited, a South African registered group.

Supervisory Authority

The Central Bank of Ireland

Registered Office and Registered Number

Registered Office: Elm Park, Merrion Road, Dublin 4, Ireland

Registered Number: 358436

Auditor

PricewaterhouseCoopers

Risk Profile

Sasol International Insurance DAC is licenced to write the following classes of business

- Class 1: Accident
- Class 2: Sickness
- Class 7: Goods In Transit
- Class 8: Fire and Natural Forces
- Class 9: Other Damage to Property
- Class 13: General Liability
- Class 16: Miscellaneous Financial Loss

Material Geographical Areas

- EU/EEA (Italy, Germany)
- Non EU/EEA (South Africa, USA, Mozambique)

Significant events in the reporting period

There were no significant events, outside the normal course of insurance business, within the reporting period that had a material impact on the Company.

A.2 Underwriting Performance

2023 (all in US\$)					
Gross Premium Written:	PDBI	General Liability	Personal Accident	Property Damage	Total
Risks located in Ireland	-	-	-	-	-
Risks located in other EU countries	1,280,570	634,794	-	-	1,915,364
Risks Located outside EU	44,577,697	14,975,092	468,289	449,267	60,470,345
Total	45,858,267	15,609,886	468,289	449,267	62,385,709

2022 (all in US\$)					
Gross Premium Written:	PDBI	General Liability	Personal Accident	Property Damage	Total
Risks located in Ireland	-	-	-	-	-
Risks located in other EU countries	1,492,059	918,153	-	-	2,410,212
Risks Located outside EU	41,445,538	14,436,842	476,264	444,998	56,803,642
Total	42,937,597	15,354,995	476,264	444,998	59,213,854

2023 (all in US\$)					
Technical Result:	PDBI	General Liability	Personal Accident	Property Damage	Total
Gross Earned Premium	45,788,432	15,609,886	468,289	449,267	62,315,874
Gross claims paid	(29,530,160)	-	-	-	(29,530,160)
Change in the gross claims provision	(30,452,448)	793,698	3,987	(3,202)	(29,657,965)
Gross operating expenses	(686,152)	(290,767)	(2,634)	(2,527)	(982,080)
Reinsurance balance	15,784,268	(2,049,157)	-	-	13,735,111
Allocated investment return	960,328	326,890	9,807	9,408	1,306,433
Net technical result	1,864,268	14,390,550	479,449	452,946	17,187,213

2022 (all in US\$)					
Technical Result:	PDBI	General Liability	Personal Accident	Property Damage	Total
Gross Earned Premium	42,937,597	15,354,995	476,264	444,998	59,213,854
Gross claims paid	(30,498,432)	-	-	-	(30,498,432)
Change in the gross claims provision	22,232,660	596,163	(62,852)	(94,498)	(22,671,473)
Gross operating expenses	(743,080)	(196,907)	(3,047)	(2,847)	(945,881)
Reinsurance balance	(19,003,568)	(5,885,888)	-	-	6,158,188
Allocated investment return	(262,224)	(93,775)	(2,909)	(2,717)	(361,625)
Net technical result	14,662,953	9,774,588	407,456	344,936	25,189,933

A.3 Financial Performance

	2023 US\$	2022 US\$
Gross premiums written	62,385,709	59,213,854
Outward reinsurance premiums	(32,234,554)	(31,047,644)
Net premiums written	30,151,155	28,166,210
Change in the gross provision for unearned premiums	(69,835)	-
Change in the provision for unearned premiums, reinsurer's share	-	-
Change in the provision for unearned premiums, net of reinsurance	(69,835)	-
Earned premiums, net of reinsurance	30,081,320	28,166,210
Allocated investment return transferred from the non- technical account	1,306,433	(361,625)
Claims paid gross	(29,530,160)	(30,498,432)
Reinsurer's share of claims paid	17,260,734	23,110,388
Claims paid net	(12,269,426)	(7,388,044)
Change in the provision for gross claims	(29,657,965)	22,671,473
Change in reinsurers' share of the provision for claims	28,708,931	(16,952,200)
Claims incurred, net of reinsurance	(13,218,460)	(1,668,771)
Net operating expenses	(982,080)	(945,881)
Balance on the technical account for general business	17,187,213	25,189,933
Investment Income / (Expense)	12,839,247	(3,625,786)
Less: Investment Income Allocated to technical account	(1,306,433)	361,625
Foreign Exchange Gain / (Loss)	(759,667)	(592,475)
Profit on ordinary activities before taxation	27,960,360	21,333,297
Taxation charge	(3,510,180)	(2,666,662)
Profit on ordinary activities after taxation	<u>24,450,180</u>	<u>18,666,635</u>

A.4 Investment Performance

Total Investment Return for the financial year ended 30 June 2023 was US\$ 12,839,247 (2022: US\$ (3,625,786)). The table below outlines a breakdown of the investment performance by asset class:

Asset Class	2023 US\$	2022 US\$
Bonds	(668,348)	(2,402,415)
Equities	4,539,824	(2,312,925)
Collective Investment Undertakings	65,213	(696,186)
Cash and Deposits	5,773,839	292,106
Intercompany Loan	3,305,166	1,589,386
Investment Managers Expense	(176,447)	(95,752)


A.5 Any Other Information

No other information

B. Systems of Governance

B.1 General Information

The Organisational Structure of the Company is as follows:



Board of Directors

The Board of Sasol International Insurance DAC as at 30th June 2023 comprised as follows:

Name	PCF	Date Appointed by the Board	Date Resigned
Pieter Van Vuuren	Executive Director (PCF1)	Appointed alternate director 26/6/2006 and director in 2009	N/A
Trevor Madden	Non-Executive Director (PCF2)	08/07/2013	N/A
Gnanesh Pillay	Executive Director (PCF1) & Chairman of the Board (PCF3)	09/02/2021	N/A

The following roles and decisions are the sole responsibility of the Board and it is their role to ensure:

- The effective, prudent and ethical oversight of the Company

- Setting the business strategy for the Company
- Establishing Banking mandate/s
- Determining Investment Policy (to be reviewed by the Board annually)
- Insurance policy terms and conditions (including Reinsurance)
- Insurance pricing
- Loss Reserve strategy
- Appointment of Reinsurers
- Capital and calling-up of capital
- Appointment of Auditors
- Appointment of Head of Actuarial Function
- Appointment of Corporate Secretary
- Appointment of Insurance Managers
- Appointment of Investment Managers
- Appointment of Bankers
- Appointment of Lawyers
- Appointment of Directors/Compliance Officer
- Dividend Recommendations
- Setting the Risk Appetite of the Company
- Overall Responsibility for the Company's Risk
- Establishing and maintaining the Company's Internal Control Framework
- Identification and appointment of the Key Functions within the Company

- Removal of the Head of a Pre-Approval Control Function ("PCF") and consequent notification of such decision to CBI within 5 working days
- Own Risk and Solvency Assessment ("ORSA") and related activities
- Own Risk and Solvency Assessment ("ORSA") approval procedures
- Review of the Company's Policies and Procedures (annually)
- Establishment (if appropriate) of various Committees and related delegation of duties
- Sign-off various Committees' Terms of Reference (if appropriate)
- Fit and Proper Procedures and approval process
- Compliance with Regulatory Requirements

Audit Committee

Section 1551(13) of the Companies Act 2014 exempts captive insurers from the requirement to establish an audit committee. This exemption exists where, inter alia, a body performs functions equivalent to an audit committee (including performing the responsibilities set out in the Companies Act 2014). The Board of Sasol International Insurance DAC has determined that it will perform equivalent functions to an audit committee and, accordingly, has taken responsibility for performing those functions. In addition, as the Board of Sasol International Insurance DAC has undertaken responsibility for performing equivalent functions to an audit committee, the Board have not deemed it necessary to establish an audit committee for the purposes of Section 167 of the Companies Act 2014."

The duties of the Audit Committee to be performed by the Board of Directors include:

- To monitor the financial reporting process.
- To monitor the effectiveness of the entity's systems of internal control, internal audit and risk management.
- To make recommendations to the Board on appointment of statutory auditor or audit firm.
- To monitor the statutory audit of the annual accounts.
- To monitor the Internal Audit Function and consider the recommendations of the internal audit reports.

Information on Remuneration Policies and Practices

As the Company is a Captive Insurance Company, all Director positions are held either by Group employees or members of outsourced service providers. No Board members are individually remunerated for the role as Director and the Company did not have any employees at any time during the year.

Overview of Year Ended 30th June 2023

Three Board Meetings took place in Dublin, Ireland within the reporting period. These took place on the following dates:

- 30th September 2022
- 1st December 2022
- 30th May 2023

There were no changes to the composition of the Board of Directors during the period.

Key Functions

The Company complies with the requirements under Solvency II and the Fitness & Probity Standards to ensure that key functions are held by persons with the appropriate knowledge, experience and competence. The Company has nominated Mr. Pieter Van Vuuren, Executive Director as the designated person, with the overall responsibility for the outsourced functions. Mr. Van Vuuren has sufficient knowledge and experience with regard to the outsourced key functions and has the ability to challenge the performance and results of the respective service providers. The following key functions are outsourced by the Company:

Risk Management Function.

The Company's Risk Management Function is outsourced to Willis Towers Watson Management (Dublin) Limited ('WTWMDL'), subject to the conditions outlined in the Company's Outsourcing Policy.

The Board will review the composition of its Risk Management Function at least annually.

The Board is responsible for ensuring the effectiveness of the Company's Risk Management System, for setting the risk appetite and tolerance levels as well as approving all related risk management strategies and policies.

The Company's Risk Management Function is responsible for the implementation of the Company's Risk Management arrangements within the operations of the Company on an ongoing basis.

The Risk Management Function is also responsible for effective reporting to the Board on the material risks to which the Company is exposed and on other specific areas of risks both on its own initiative and following direction from the Board.

In line with the Solvency II requirements, the Company has nominated an appropriate person to the role of Chief Risk Officer (PCF14). This function holder is provided to the Company by WTWMDL in line with the terms and conditions of the Management Services Agreement.

Compliance Function.

The Company's Compliance Function is responsible for implementing an appropriate compliance framework within the Company and monitoring the Company's adherence to legal and regulatory requirements on an ongoing basis.

The Compliance Function reports to the Board periodically on all key compliance matters, such as implementation of the annual Compliance Plan, regulatory engagement and correspondence, upstream regulatory developments and any compliance breaches that may have occurred in the period and corrective actions undertaken.

In line with the Solvency II requirements, the Company has nominated an appropriate person to the role of Head of Compliance (PCF12). This function holder is provided to the Company by WTWMDL in line with the terms and conditions of the Management Services Agreement.

Actuarial Function.

The Board has ensured that an appropriately resourced Actuarial Function is established and maintained within the Company. The activities of the Company's Actuarial Function are currently outsourced to Willis Towers Watson Strategic Risk Consulting.

The Actuarial Function is carried out by persons who have an appropriate knowledge of actuarial and financial mathematics, commensurate with the nature, scale and complexity of the risks inherent in the Company, and who are able to demonstrate their relevant experience with applicable professional and other standards in line with the Company's Fitness and Probity Policy and the Central Bank of Ireland's Fitness & Probity Standards.

In line with the Solvency II requirements, the Company has nominated an appropriate person to the role of Head of Actuarial Function (PCF48).

The Actuarial Function's role can be summarised as providing the Company with the following:

- Contribution to the effective implementation of the risk management system, in particular, the Own Risk and Solvency Assessment (ORSA) and SCR (Solvency Capital Requirement) calculations.
- Co-ordinating the calculation of the Technical Provisions.

- Provision of an opinion on the underwriting and reinsurance policy of the Company.
- Issuing of a written report to be submitted to the Board, at least annually (Actuarial Function Report). The report documents all tasks that have been undertaken by the Actuarial Functions and their results, and clearly identifies any deficiencies and gives recommendations as to how such deficiencies should be remedied.
- Assess the sufficiency and quality of the data used in the calculation of technical provisions.
- Comparison of best estimates against experience.

Internal Audit Function.

The Board has ensured that an appropriately resourced Internal Audit Function is established and maintained within the Company. The Internal Audit Function is an outsourced service provided by a third party audit firm (Mazars) with the Board of Directors acting as oversight. The Internal Audit mission is to independently examine and evaluate the adequacy and subsequent functioning effectiveness and efficiency of the Company's internal control system and all other elements of governance.

The activities of the Internal Audit function are designed to provide assurance on internal controls and advice to management in improving the internal control environment, monitoring the implementation of strategic control initiatives and managements remediation activity. The Internal Audit Function provides a formal report to the Board at least annually. The findings of Internal Audit reviews conducted are discussed with and challenged by the Board and an action plan is agreed upon to remediate any issues identified, along with a timeline for completion.

In line with the Solvency II requirements, the Company has nominated an appropriate person to the role of Head of Internal Audit Function (PCF13).

B.2 Fit and Proper Requirements

Sasol International Insurance DAC deems the following personnel to hold Pre-Approval Controlled Functions and therefore be defined as 'Relevant Persons' subject to the Fitness and Probity Standards:

- The Board of Directors
- The Chief Risk Officer
- The Head of Internal Audit
- The Head of Actuarial Function
- The Head of Compliance

Fitness:

The members of the Board of the Company collectively possess the required qualification, experience and knowledge:

- Of insurance and financial markets relevant to the operations of the Company;
- Of the business strategy and business model of the Company;
- Of the Company's system of governance;
- To perform required financial and actuarial analysis in respect of the Company;
- Of the regulatory framework and requirements applicable to the Company; and
- Generally to be able to provide for the sound and prudent management of the Company.

The persons holding the key functions outlined above hold the appropriate qualifications, knowledge and sufficient experience in their relevant disciplines, in compliance with the Fitness and Probity Standards ("The Standards").

Probity:

The honesty, financial soundness and reputation of every Relevant Person as defined above has been assessed by the Company in order to determine that they are of good repute and integrity. This assessment has been based on relevant evidence regarding their character, personal behaviour and business conduct including any criminal, financial and supervisory aspects, regardless of location.


In line with The Standards, the Company submits a PCF Confirmation to the Central Bank on an annual basis confirming all PCF holders remain in compliance with the fitness and probity requirements.

B.3 Risk Management System

The Company's Risk Management System is comprised of the following elements;

- Risk Appetite Statement (RAS)
- Risk Register
- Formal Policy Documents for all key risks
- Own Risk and Solvency Assessment (ORSA)

■ Formalised Risk Reporting



Each of the elements of the Risk Management System detailed above contribute to the identification, measurement, monitoring, management and reporting of risks and is intended to work as an integrated system, and therefore each should be considered both in terms of the specific function of the respective element, and in terms of its function within the overall system.

Each element of the system is embedded effectively within the Company and managed by the Risk Management Function with appropriate oversight from and reporting to the Board.

Risk Management Approach

The Company's risk management approach is centred on ensuring the inherent risks which the Company faces in the course of its business are appropriately managed to ensure the strategic objectives of the Company are achieved.

This approach also ensures that risk management is appropriately included in the Company's decision making process.

Risk Profile

The Company, in considering its risk profile, has regard to the following factors;

Nature:

The nature of the Company's risk is confined within the Sasol Group only with no third-party policy holders and therefore represents limited systemic risk.

Scale:

The scale of the risk assumed by the Company can be considered low based on the residual 'Values at Risk' and the Company's organisational structure, relative to the general insurance market.

Complexity:

The Company assumes standard underwriting risk only, holds a simplistic and conservative investment portfolio, employs traditional risk mitigation techniques and utilises reputable counterparties, and therefore the risk assumed can be considered to be of limited complexity.

The Company's risk profile is formally reviewed at least annually as part of the Company's ORSA exercise. The Risk Management Function monitors the Company's risk profile and the corresponding risk management arrangements in place on an ongoing basis and reports to the Board on any observed material changes.

Risk Function

The Risk Management Function of the Company is responsible for the operational coordination and application of all Risk Management activities throughout the Company on an ongoing basis.

The Risk Management Function reports directly to the Board on a bi-annual basis or upon occurrence of an event which could materially impact the Company's risk profile.

The Risk Management Function is responsible for the coordination of all risk management activities throughout the Company.

The Risk Management Function is also responsible for providing the Board with assistance and support in the development and implementation of the various risk management arrangements within the Company.

The Board has outsourced the activities of the Risk Management Function to Willis Towers Watson Management (Dublin) Limited in accordance with the Company's Outsourcing Policy and the terms and conditions of the Management Services Agreement.

Risk Categories & Key Risks

Key risks are considered to be the six risk categories detailed in the Solvency II Directive, together with any other risks evaluated as being key risks by the Risk Management Function and the Board of Directors.

Any of the other identified risks, outside of those prescribed risk categories in the Solvency II Directive, shall be considered to be a key risk if, on a residual basis, a material level of capital is deemed to be required in order to accept the risk, or if particular controls or risk mitigation techniques specific for the risk in question must be employed in order to bring the risk within the appropriate thresholds as defined in the Risk Appetite Statement.

All key risks are documented in the Risk Appetite Statement and are subject to a specific policy document which addresses how the risk is to be managed in line with the hierarchy outlined previously.

The key risk categories for the Company are;

- Underwriting and Reserving Risk
- Reinsurance and Other Risk Mitigation Techniques
- Operational Risk
- Investment Risk
- Asset-Liability Management Risk
- Liquidity Risk

The risk categories and key risks to which the Company is exposed are reviewed periodically by the Risk Management Function and at least;

- Bi - Annually
- On occurrence of an event which could materially affect the Company's risk profile
- On the introduction of material new business
- At the discretion or order of the Board

Risk Appetite Statement

The Company has in place a Risk Appetite Statement (RAS). The RAS sets out the risk appetite and tolerance levels for all key risks over the planning period of the Company.

The Company considers the RAS to be the primary element of the Risk Management System, directly linking to the overall Company Strategy and determining the levels retained for each key risk, and also influencing the nature of the controls and mitigation techniques employed to ensure that the risk remains within the tolerable range.

The Board is responsible for setting the Company's RAS. The Board periodically reviews the appropriateness and effectiveness of the RAS and performs a formal review of the RAS at least annually or upon a material change in the Company's risk profile.

The RAS includes both qualitative and quantitative aspects for each key risk and is aligned to the planning period of the Company.

The RAS is embedded within the decision making processes of the Company. The Board of Directors, prior to finalising any material decision which could impact the risk profile of the Company, refers to the RAS for guidance as to the likely effect of the decision on the risk appetite and tolerance levels of the Company.

The RAS is also used to track actual performance against the metrics detailed in the RAS to ensure that no breach in the agreed tolerance levels has occurred that would require the submission of a report to the Central Bank of Ireland.

Monitoring of the actual performance against the metrics identified in the RAS is performed periodically by the Risk Management Function and reported to the Board in line with the reporting trigger system included in the RAS.

The Company's qualitative risk appetite principles and quantitative appetite and tolerance levels for each key risk are detailed in the RAS.

Risk Policies

The Company has documented a formal policy for each key risk included in the RAS. The policies for each specific risk are consistent with the details contained in the RAS relating to the risk in question. The controls, reporting triggers and any other relevant aspects of the management of the risk are appropriately reflected in the policy for the risk.

Risk Register

The Company has in place a comprehensive Risk Register to evaluate and assess the risks to which the Company is exposed.

The Risk Register initially assesses the risk universe of the Company on an inherent basis. The controls and risk mitigating techniques employed by the Company, as documented in the Company's policies and procedures allow for an evaluation of the risk on a residual basis.

If the risk on a residual basis is deemed to potentially require a material level of capital or the implementation of significant additional controls to accommodate the risk to bring the risk within the appropriate thresholds, this risk should be considered a key risk. Any risk deemed to be a key risk shall be considered for inclusion in the RAS by the Board and a specific policy developed which outlines the process for the identification, management, monitoring and reporting on the risk in question.

The Risk Management Function is responsible for the ongoing maintenance of the Risk Register.

The Risk Register is updated on at least a bi-annual basis and upon the occurrence of an event which may materially impact the Company's risk profile.

A summary of the results of the Risk Register review is distributed to the Board upon completion of the each review as soon as is practicable and form part of the Risk Management Function's periodic Risk Reporting.

As part of each update, the Risk Register is reviewed by the Risk Management Function to ensure that the Risks included represent all the material risks to which the Company is exposed and that all applicable emerging risks have been appropriately included.

Where an emerging risk has been identified as one which should potentially be included in the Risk Register, the Risk Function advises the Board of the nature and context of the risk. The Board then determines whether the risk in question is to be included in the Risk Register and whether the risk should be considered as a Key Risk.

ORSA

The Company aims to ensure that the Company is appropriately and prudently capitalised in order to accept the risk to which the Company is exposed. In order to ensure this, the Company performs an Own Risk and Solvency Assessment ('ORSA') at least annually and upon the occurrence of an event which may materially impact the Company's risk profile.

ORSA - Approach taken:

The EIOPA guidance in relation to the ORSA focuses on what is to be achieved by this assessment rather than on how it is to be performed. Since the ORSA represents the Company's own view of its risk profile and the capital needed to address these risks, the Company decides for itself the most appropriate process by which the ORSA is performed.

The Board takes a proactive approach in the ORSA process by providing guidance to the Risk Management function as to the direction of the ORSA process, including the identification, evaluation and quantification of the risks inherent in the business.

The following approach provides a summary of the approach taken in 2023:

- A Board Meeting was held in May 2023 where the Chief Risk Officer reminded the Board of the key purposes of the ORSA exercise and provided an overview of the plan and process for 2023.
- At the Board Meeting to be held in September 2023 the Board will review the Risk Register and Risk Appetite Statement and approve the 2023 ORSA framework and related items including determination of the Own Solvency Needs as well as appropriate scenarios for analysis and stress testing.

- The Board will review and approve the full suite of ORSA documentation including the ORSA Report, Regulatory Reporting Template and Directors' Compliance Statement before the 31st December 2023.

The Board of Directors provide substantial input and discuss in detail the various aspects of the ORSA, and adjust as and when considered necessary, as documented in the minutes of the Board meetings where the ORSA process is an Agenda item.

Own Solvency Needs Assessment

The first element of the ORSA process was to ascertain the Company's assessment of its Own Solvency Needs (OSN). OSN is a method of identifying its material risks in the context of its Risk Profile, Risk Register and Risk Appetite Statement. The following areas for assessment were identified in respect of the Company's material risks:

- The Maximum Value at Risk (VAR) for each identified key risk of the Company,
- The controls and risk management arrangements in place which act to mitigate each risk,
- The basis for measurement and assessment of the risk over the planning period,
- The current experience of each individual risk,
- The expected risk assessment for the planning period, being the anticipated financial and non-financial activity of the Company over the short, medium and long term.
- Application of appropriate and reasonable stresses to the expected risk assessment to demonstrate the robustness of the Company's capital base in the context of its current business.

Risk Reporting

The Risk Management Function formally reports to the Board on a bi-annual basis. The report contains details of the outcome of the Risk Register review, the results of the comparison of the RAS to actual results and an update on emerging risks.

The report contains both qualitative and quantitative aspects and covers all key risks of the Company.

The Risk Management Function is responsible for the development of the Risk Reports.

The Risk Management Function will provide a report to the Board based on the occurrence of an event which materially alters the risk profile of the Company or if the tolerance level triggers are at risk of being breached.

The Risk Management Function will advise the Board on the quality of the data used in the review of the Risk Management System, including any deficiencies that may have been identified during the course of the review.

B.4 Internal Control System

The Board is ultimately responsible for ensuring that the Company has in place an effective internal control system which is commensurate with the nature, scale and complexity of the Company's operations. The Company ensures that appropriate levels of Internal Controls are present within the organisational structure, work and authority flows, resource utilisation and information systems.

This is achieved by:

- Ensuring the existence and application of individual internal policies, procedures and guidelines for each of the critical functions and activities of the Company;
- Ensuring that adequate approval procedures, authorization authorities, verification, reconciliations, and review procedures are in place for each function or activity and are adequately documented and communicated;
- Ensuring that adequate controls are in place pertaining to safeguarding the integrity and protection of information;
- Ensuring sufficient monitoring mechanisms are in place to facilitate assessments of the adequacy and effectiveness of the controls in place; and
- Ensuring the activities of the Compliance function are in place, the Compliance Policy is being applied and the Compliance Plan is being implemented.

The Internal Audit Function and Management/Board is responsible for the evaluation of the adequacy and effectiveness of the Company's internal control system. The Compliance Function is responsible for the review and monitoring of the application of internal controls relating to compliance risk. The outsourced Managers are responsible for the application and ongoing maintenance of the Company's internal control activities. The contracted Management Company has procedures manuals and internal controls in place that are documented and maintained within the Company's Corporate Governance Framework documents. Internal controls are reviewed at least annually or when a change in the systems or operations of the Company occurs. The policies and procedures in place are proportional to the operations of the Company and cover at least the following key operational areas:

- Underwriting
- Reinsurance
- Claims reserving

- Claims settlement
- Management accounts preparation
- General bank payments
- Bank reconciliations
- Risk and Compliance
- Investment

The Internal Controls are also proportional to the operations of the Company and centre on the following controls:

Regular

- Four eye review approach on all renewal activities
- Dual signatories on all payments in line with approved bank mandates
- Reconciliations of all bank accounts on a monthly basis
- Quarterly Financial reporting to Group
- Detailed bi-annual reporting to the Board on Financial, Risk and Compliance matters

Periodic

- Monitoring activities are carried out by the Compliance Function and a Compliance and Regulatory report is circulated to the Board.
- The Internal Audit Function conduct reviews of the design and effectiveness of internal controls, in line with the Internal Audit Plan approved by the Board
- The Management Company is subject to the Internal Audit processes of the Willis Towers Watson Group with Internal Audit reviews covering work performed by WTWMDL on its clients

External Audit

- The Company's accounts are audited annually by the external Auditor, providing assurance to the Board that the financial statements provide a true and fair view of the company's assets, liabilities and financial position and that no material matters have been raised on the operations of the Company.

B.5 Outsourcing

The Company outsources various activities where the Board believes outsourcing can provide access to superior processes and technical skills than it would otherwise achieve on a standalone basis, or where appropriate due to the nature, scale and complexity of the operations of the Company. The Board is ultimately responsible for the approval of and termination of all outsourcing arrangements of critical or important functions and activities.

The Risk Management Function is responsible for assessing the risks associated with the outsourcing of critical or important functions or activities as part of its overall remit to identify, assess, manage, monitor and report the risks of the Company on an ongoing basis. The functions deemed critical or important are defined in the Company's Outsourcing Policy.

The Board has ensured that the outsourced service providers adhere to the Company's policies and procedures and that the effectiveness of the Company's system of governance has not been lessened or compromised by the outsourcing arrangements.

The performance of each service provider is based on a comparison of the actual performance of the service provider with the required performance as per the agreed Service Level Agreement ('SLA'). The SLAs include details covering Business Continuity Planning and ensure that acceptable service levels are maintained in the event of problems occurring with the service provider. The performance of the service providers are formally assessed and noted by the Board on an annual basis.

In the Board's current assessment of the performance of each service providers acting in an outsourced capacity, no material deficiencies are noted.

B.6 Any Other Information

No other information

C. Risk Profile

The Company operates a low-risk business model that is supported by a robust risk management framework that ensures risks are well understood and controlled. This is facilitated by systematic quantification of all risks and a culture that promotes the importance of risk management.

Integral to this is a thorough understanding and articulation of the Company's risk exposures. Determining the prevailing risk landscape within the Company allows Management, the Risk Function and the Board to assess the appetite for each emerging risk and to ensure that all are quantifiable and managed consistently with our appetite to risk.

An overview of the key risks associated with the business including an outline of how they are managed is provided below.

C.1 Underwriting Risk

The risk under any one insurance contract is the possibility that the insured event occurs and the uncertainty of the amount of the resulting claim. By the very nature of an insurance contract, this risk is random, unknown and unpredictable.

As its primary insurance activity the Company assumes risks relating to Property Damage and Business Interruption (PDBI) coverage and General Liability (GL) coverage relating to the Group's Production Facilities in South Africa, Italy, Germany, USA and Mozambique. Additionally the Company accepts inwards reinsurance placements for Personal Accident and Non Production Assets All Risks coverages in South Africa only. The Company is therefore exposed to the uncertainty surrounding the timing and severity of claims under these insurance contracts. The terms and conditions of the insurance contracts it issues set out the basis for the determination of the Company's liability should the insured event occur.

The Company also faces risks that the actual claims are significantly different to the amounts included within the technical provisions. This could occur because the frequency or severity of claims is greater or lower than estimated. The insurance risks are mitigated through strict underwriting criteria, the utilising of actuarial review and the use of reinsurance.

The Company manages its insurance risk through underwriting limits, approval procedures for transactions that involve new products or that exceed set limits, pricing guidelines, centralised management of reinsurance, monitoring of emerging issues and actuarial reviews.

The Company reinsures a significant portion of the risks it underwrites in order to control its net exposure to losses and protect capital resources. The Company buys non-proportionate facultative reinsurance to reduce the Company's net exposure.

Ceded reinsurance contains credit risk on reinsurance recoverable that are reported after deductions, if any, for known insolvencies and uncollectible items. The Company monitors the financial condition of reinsurers on an ongoing basis and reviews its reinsurance arrangements annually. The Company utilises reinsurance agreements with non-affiliated reinsurers to control its exposure to losses resulting from one occurrence and for the accumulation of net losses arising out of one occurrence.

C.2 Market Risk

The Company's primary objective in relation to market risk is to protect and preserve the Company's assets. The Company therefore only invests in line with the Company's Investment Policy which is reviewed on an annual basis by the Board of Directors..

The Company has appointed an appropriately experienced investment manager to manage the Company's portfolio of debt and equity securities in order to keep market risk to a minimum.

The Company seeks to spread investments across a number of institutions to reduce concentration risk.

The Company and the Board will annually review the amount of funds invested with any one institution and will maintain a minimum of three credit institutions.

The Company has little appetite for counterparty default risk in relation to investments and seeks to invest in institutions with an investment grade rating as a minimum requirement.

All of the Company's liabilities can be considered short term in nature and hence the company looks to limit the duration of investments to reduce Asset Liability Matching risk.

C.3 Credit Risk

Credit Default Risk

The investment strategy and minimum rating requirement outlined in the Company's Investment Policy is pursued and seeks to minimise credit default risk, which is achieved in a number of ways such as investing in low risk asset classes such as government guaranteed bonds.

Counterparty Default Risk

The Group utilises reinsurance to efficiently manage insurance risk. The Group is therefore exposed to the failure to perform by these counterparties. The exposure is reduced as the counterparties are diversified and also the credit default risk is managed by ensuring a minimum credit rating of A or greater for reinsurers, as documented in the Reinsurance Policy (Two exceptions currently in respect of Santam Ltd. who are rated BB and ITOO Special Risks Pty Ltd. who are unrated. These exceptions are noted and approved by the Board.)

C.4 Liquidity Risk

The Company's Liquidity Policy requires sufficiently liquid assets to be held in order to meet outflows. All investments are held in a liquid state and the Company has clear visibility of when policyholder obligations will and could fall due given the nature and scale of the Company being a Captive Insurer. Ongoing monitoring of liquidity also allows mitigating actions to be taken at an early stage if required.

C.5 Operational Risk

The Company is exposed to operational risk, which is defined as the risk of loss resulting from inadequate or failed internal processes, people and systems or from external events. In particular, this includes the failure of key outsourcing arrangements, business disruption, fraud and loss of key personnel.

The process through which the Company's operational risk universe is determined and the estimates of frequency and severity of possible events are assessed and captured in the Operational Risk Policy. This process safeguards the ongoing sustainability and improvement of the control environment and ensures that operational risk is identified and mitigated.

The Company is reliant on the use of external parties to provide a significant portion of the services required and is therefore exposed to the potential failure of these outsourcing partners. The Company has documented a Contingency Plan and an Outsourcing Policy which set out how this risk is managed and monitored.

C.6 Other Material Risks

The Company considers that there are no other Material Risk to be considered at this time.

Both pandemic risk and geopolitical risks, specifically the COVID-19 pandemic and the Russia/Ukraine conflict, have been considered in coming to the above conclusion.

C.7 Any Other Information

No other information

D. Valuation for Solvency Purposes

D.1 Assets

Valuation of Assets

The recognition and valuation basis are in accordance with the provisions of the Solvency II Directive with the valuation and recognition for material classes as follows:

Intangible Assets

Intangible assets are recognised under Financial Reporting Standard 102 (FRS102) on the basis that the expected future economic benefits that are attributable to the asset will flow to the Company, and the cost of the asset can be measured reliably. The Company holds no intangible asset and thus no recognition and valuation methodology was applied in respect of this category.

Deferred Tax Asset

Deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Deferred tax is calculated at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period.

Investments

Investments are recognised under FRS102 on the basis that the Company becomes a party to the contractual provisions of the instrument.

All financial assets and liabilities are initially measured at transaction price, except for those financial assets classified as fair value through profit and loss, which are initially measured at fair value.

Realised and unrealised gains and losses arising from the changes in the fair value of investments are presented in the non-technical profit and loss account in the period in which they arise. Interest income is recognised when earned and investment management and other related expense are recognised when incurred.

Material Differences in the above used for valuation in Financial Statements

The table below sets out the values in the financial statements along with the corresponding current accounting basis used to calculate the Solvency II valuation.

Sasol International Insurance DAC Assets (US\$)	2023	
	Current Accounting Bases	SII Valuation Principles
Deferred Acquisition Costs	341,483	-
Deferred Tax Assets	-	363,635
Total Investments	248,555,145	248,555,145
Participations and related undertakings	5,000	5,000
Equities (Other than Participations) – Listed	23,058,828	23,058,828
Government and Multilateral Banks	19,131,573	19,131,573
Collective Investment Undertakings	7,754,766	7,754,766
Deposits Other Than Cash Equivalents	198,604,978	198,604,978
Other Mortgages and Loans	-	-
Reinsurance share of TP - non-life excluding health	42,251,670	41,335,827
Insurance & Intermediaries Receivables	592,388	482,698
Reinsurance Receivables	11,880,000	11,880,000
Cash & Cash Equivalents	16,855,183	16,855,183
Any Other Assets, Not Elsewhere Shown	3,117,898	3,117,898
Total assets	323,593,767	322,590,386

Sasol International Insurance DAC Assets (US\$)	2022	
	Current Accounting Bases	SII Valuation Principles
Deferred Acquisition Costs	303,700	-
Deferred Tax Assets	-	441,236
Total Investments	95,026,909	95,026,909
Participations and related undertakings	5,000	5,000
Equities (Other than Participations) – Listed	20,692,280	20,692,280
Government and Multilateral Banks	19,751,663	19,751,663
Collective Investment Undertakings	3,521,744	3,521,744
Deposits Other Than Cash Equivalents	51,056,222	51,056,222
Other Mortgages and Loans	115,000,000	115,000,000
Reinsurance share of TP - non-life excluding health	13,542,739	12,025,948
Reinsurance Receivables	-	-
Cash & Cash Equivalents	41,029,319	41,029,318
Any Other Assets, Not Elsewhere Shown	2,549,928	2,549,928
Total assets	267,452,595	266,073,339

Key points to note:

- The Solvency II reinsurance share of technical provisions ("TP") value is a discounted best estimate which is derived by the Company's Head of Actuarial Function ("HoAF").
- All other assets remain unchanged when presented under Solvency II valuation principles with the exception of:
 - o deferred acquisition costs which are removed under Solvency II and the creation of a deferred tax asset which is generated as a result of the revaluation of the technical provisions under Solvency II.
 - o premium receivable where only receivable amounts relating to expired periods remain on the SII balance sheet while receivable amounts relating to the current period are accounted for within the technical provisions.

Overview of any assets not regularly traded in Financial Markets

With the exception of the investment portfolio the Company has no financial assets that are not regularly traded in financial markets other than a nominal shareholding in a mutual insurance company.

D.2 Technical Provisions

Valuation of Technical Provisions per Line of business

Technical provisions are valued in accordance with Article 77 of the Solvency II Directive which states that the value of technical provisions shall be equal to the sum of a best estimate and a risk margin.

Valuation results

The valuation was carried out for each line of business. Under Solvency II, the balance sheet is required to be valued on a "best estimate" discounted cash flow basis. This leads to differences in claims provision between financial statements and Solvency II.

The table below sets out the results of the Technical provision calculations on the financial statements and Solvency II basis.

Sasol International Insurance DAC Liabilities (US\$)	2023	
	Current Accounting Bases	SII Valuation Principles
Gross Technical Provisions – Non-Life (Excluding Health)	67,766,834	70,979,242
TP calculated as a whole (Best estimate + Risk margin)	67,766,834	-
Best Estimate	-	65,492,756
Risk Margin	-	5,486,486
Gross Technical Provisions - Health (Similar to Non-Life)	234,145	192,897
TP calculated as a whole (Best estimate + Risk margin)	234,145	-
Best Estimate	-	172,242
Risk margin	-	20,655
Insurance and Intermediaries Payable	462,153	462,153
Reinsurance payables	1,629,094	-
Any other liabilities, not elsewhere shown	369,248	369,248
Total liabilities	70,461,474	72,003,540

Sasol International Insurance DAC Liabilities (US\$)	2022	
	Current Accounting Bases	SII Valuation Principles
Gross Technical Provisions – Non-Life (Excluding Health)	38,035,047	39,784,098
TP calculated as a whole (Best estimate + Risk margin)	38,035,047	-
Best Estimate	-	34,938,757
Risk Margin	-	4,845,341
Gross Technical Provisions - Health (Similar to Non-Life)	238,132	198,483
TP calculated as a whole (Best estimate + Risk margin)	238,132	-
Best Estimate	-	180,780
Risk margin	-	17,703
Insurance and Intermediaries Payable	392,153	392,153
Reinsurance payables	-	-
Any other liabilities, not elsewhere shown	105,150	105,150
Total liabilities	38,770,482	40,479,884

Key points to note:

The Solvency II Gross Technical Provisions value is a discounted best estimate which is derived by the Company's HoAF and also includes a portion of Events Not In Data ("ENIDs") of US\$ 97,500 (2022: US\$ 97,500) along with run-off expenses of US\$ 691,461 (2022: US\$ 711,605); the latter being specifically required by the Solvency II Directive.

The most significant adjustments in converting the technical provisions from a GAAP to a Solvency II basis is the removal of the margin for uncertainty above the actuarial best estimate and the addition of the Risk Margin to the Gross Technical Provisions.

Claims Provision

As at the reporting date, the Company had four (2022: five) known losses reported with reserves of US\$ 54,167,368 (2022: US\$ 25,900,925) booked in the audited financial statements together with Incurred but not Reported (IBNR) provisions in the amount of US\$ 13,763,776 (2022: US\$ 12,372,254).

Material Differences in the above used for valuation in Financial Statements

The above table outlines the material differences in the valuation of technical provisions between the Financial Statements and Solvency II valuation.

Uncertainties in the value of Technical Provisions

The key assumptions that impact the Technical Provisions are detailed below along with comments regarding the materiality of these assumptions.

- **Settlement period:** Most of the risks being underwritten are short-tailed. We have assumed that risk would run off within 4 years.
- **Discount rate:** EIOPA standard yields are applied to the various lines of business depending on the underlying currency of the policy written. The effect of the discounting is to reduce the value of the technical provisions held when valued using Solvency II principles.
- **Expenses:** The total expenses involved in the operation of the Company are relatively small when compared to other elements in the calculation of the technical provisions.
- **Reinsurance:** We have also assumed that the reinsurance will perform as expected.

The above assumptions are consistent with the previous Actuarial Function Report therefore there have been no material changes in technical provisions due to underlying changes in the assumptions.

Impact of Reinsurance on Technical Provisions

The impact of reinsurance under SII valuation principles is to decrease the Company's Reinsurers' Portion of Technical Provisions by US\$ 915,843 (2022: decrease of US\$ 1,516,791).

Effectiveness of reinsurance arrangements

The Company's "Reinsurance and Other Risk Mitigation Techniques" Policy, last approved on 1st December 2022, refers to the below key principle:

- That the reinsurance programme provides cover appropriate to the Company's level of capital, risk profile, business strategy and risk appetite statement.

It is noted that: "The use of reinsurance is to maintain underwriting risk within the Company's approved risk tolerance levels." The Board were satisfied with the effectiveness of the reinsurance arrangements in place.

It is also noted that, the Sasol Group could purchase insurance directly from the market and therefore the use of the Company for the provision of insurance services is a conscious decision made in order to improve the efficiency of the risk management process within the Group by using a Company vehicle and provide access to reinsurance markets.

Matching Adjustments, Volatility Adjustments and Transitional Measures

The Company does not apply the matching adjustment referred to in Article 77b of Directive 2009/138/EC.

The Company does not use the volatility adjustment referred to in Article 77d of Directive 2009/138/EC.

The Company does not apply the transitional risk-free interest rate-term structure referred to Article 308c of Directive 2009/138/EC.

The Company does not apply the transitional deduction referred to in Article 308d of Directive 2009/138/EC.

D.3 Other Liabilities

Valuation of liabilities per Class of Liability

Recognition

Financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument. Financial liabilities are classified according to the substance of the contractual arrangement entered into.

Initial measurement

All financial liabilities are initially measured at transaction price.

LIABILITIES	2023	2022
	US\$	US\$
Creditors arising out of Insurance operations	2,091,247	392,153
Other Creditors including taxation and social security	369,248	105,150
Total	2,460,495	497,303

Material Differences in the above used for valuation in Financial Statements

All other liabilities remain unchanged when presented under Solvency II valuation principles with the exception of reinsurance premium payable where only payable amounts relating to expired periods remain on the SII balance sheet while payable amounts relating to the current period are accounted for within the technical provisions..

D.4 Alternative methods for valuation

No alternative methods for Valuation are utilised.

D.5 Any other Information

No other information

E. Capital Management

E.1 Own Funds

Objectives, Policies and Processes for Management of Own Funds

The Own Funds are managed in accordance with the Company's Capital Management Policy and the main objective is continuously maintaining the SCR coverage using a time horizon of three years in accordance with the Own Risk and Solvency Assessment. There have been no material changes to the Capital Management Policy, its main objective or the length of the business planning period, over the course of the reporting period. Any change in the policy is reserved for the Board of the Company.

Structure, Amount and Quality of Own Funds

The Company has Tier 1 unrestricted own funds composed of ordinary share capital and retained earnings, as well as Tier 3 own funds; deferred tax asset.

The table below sets out the Company's Pillar I capital position as at the current and prior financial year-end:

Composition	2023 US\$		2022 US\$	
	Available Capital	Eligible Capital	Available Capital	Eligible Capital
Tier 1 unrestricted	250,223,211	250,223,211	225,152,219	225,152,219
Tier 1 restricted	-	-	-	-
Tier 2 basic	-	-	-	-
Tier 2 ancillary	-	-	-	-
Tier 3	363,635	363,635	441,236	441,236
Total	250,586,846	250,586,846	225,593,455	225,593,455

SCR and MCR Cover

The following tables depict the SCR and MCR coverage for the current and prior reporting periods:

2023				
Solvency	Capital Requirement	Eligible Capital	Solvency Ratio	MCR as % SCR
SCR	103,387,615	250,586,846	242.4%	25.0%
MCR	25,846,904	250,223,211	968.1%	
2022				
Solvency	Capital Requirement	Eligible Capital	Solvency Ratio	MCR as % SCR
SCR	123,870,151	225,593,455	182.1%	25.0%
MCR	30,967,538	225,152,219	727.1%	

Shareholder's Equity versus Excess of Assets Over Liabilities

The difference between the Company's equity as shown in its audited financial statements and the excess of assets over liabilities, as calculated for solvency II purposes, is called Reconciliation Reserve and is composed of:

- the difference between the technical provisions calculated in accordance with Solvency II valuation principles; and
- the removal of deferred acquisition costs and the addition of a deferred tax asset created by the revaluation of the technical provisions on a Solvency II basis.

Reconciliation of Basic Own Funds to Equity as per financial statements as at 30th June 2023	2023 US\$	2022 US\$
Solvency II - Basic Own Funds	250,586,846	225,593,455
Total Equity as per financial statements	253,132,293	228,682,113
Difference:	(2,545,447)	(3,088,658)
Represented by:		
Difference between Net Technical Provisions and BEL	1,420,137	1,636,851
Risk Margin	(5,507,140)	(4,863,045)
Removal of Deferred Acquisition Costs	(341,483)	(303,700)
Adjustment to Insurance Receivables & Payables	1,519,404	-
Adjustment to Deferred Tax	363,635	441,236
Difference:	(2,545,447)	(3,088,658)

Transitional Arrangements

None of the Company's own funds are subject to the transitional arrangements referred to in Articles 308b(9) and 308b(10) of Directive 2009/138/EC.

Ancillary Own Funds

There are no ancillary own funds items.

Deductions and Restrictions

No deductions are applied to own funds and there are no significant restrictions affecting their availability and transferability.

Deferred Tax Asset

A deferred tax asset in the amount of US\$ 363,635 (2022: US\$ 441,236) has been calculated as a result of the revaluation of the Company's assets and liabilities applying Solvency II valuation principles. The full deferred tax asset has been recognised on the Company's Solvency II Balance Sheet for the current reporting period.

The Company has determined that sufficient probable future taxable profits would be earned in order to fully utilise the deferred tax asset being recognised.

In revaluing its assets and liabilities using Solvency II principles, the Company is recognising a net deferred tax asset, as quantified above. The net deferred tax asset is available as basic own funds, classified as tier 3 in accordance with Article 76(a)(iii).

In line with the eligibility limits set out in Article 82, tier 3 own funds items, including the net deferred tax asset, do not exceed 15% of the SCR – 2023: 0.4% (2022: 0.4%) – as such the full net deferred tax asset is recognised as eligible own funds.

The amount of deferred tax asset is not deemed to be material.

E.2 Solvency Capital Requirement & Minimum Capital Requirement

Requirements for the Reporting Period

The Minimum Capital Requirement ("MCR") and SCR are calculated using the standard formula.

The Company has achieved SCR coverage of 242.4% (2022: 182.1%) and MCR coverage of 968.1% (2022: 727.1%) as at 30th June 2023.

SCR Risk Modules

The table below shows the SCR components by risk module (using the Standard Formula) at 30th June 2023:

SCR Overview	US\$ 2023	US\$ 2022
Market Risk	43,357,089	83,586,405
Counterparty Default Risk	17,682,069	20,262,614
Health underwriting risk	20,022,363	6,216,418
Non-life underwriting risk	79,890,544	67,506,097
Diversification	(46,432,097)	(45,845,502)
Basic Solvency Capital Requirement	114,519,968	131,726,032
Operational Risk	1,969,950	1,776,416
Loss Absorbing Capacity of Deferred Taxes	(13,102,303)	(9,632,295)
Solvency Capital Requirement	103,387,615	123,870,151

Simplifications

The Company utilises the standard formula for the calculation of its Solvency Capital Requirement ('SCR'). Simplification method two is used for the standard formula

Simplified calculations are not used for any of the risk modules or sub-modules.

Undertaking-Specific Parameters

The Company does not use undertaking specific parameters in its computation.

MCR Inputs

The Minimum Capital Requirement is calculated using the Standard Formula specifications.

The table below shows the inputs into the MCR calculation as at 30th June 2023:

SCR Overview	US\$ 2023	US\$ 2022
Linear MCR	5,374,971	5,117,125
SCR	103,387,615	123,870,151
MCR cap	46,524,427	55,741,568
MCR floor	25,846,904	30,967,538
Combined MCR	25,846,904	30,967,538
Absolute floor of the MCR	4,346,400	4,107,370
Minimum Capital Requirement	25,846,904	30,967,538

Material Changes to SCR and MCR

The observed changes to the Solvency Capital Requirement and to the Minimum Capital Requirement over the reporting period are predominantly driven by the increases in the Health and Non-Life Underwriting Risk Charges owing to additional retentions accepted by the Company for the 2023/2024 insurance programme. These increases were however offset by a significant reduction in the Market Risk Charge due to the repayment of the intercompany loan asset which had attracted a significant concentration risk charge due to the credit quality rating of the counterparty to the loan facility.

Loss-Absorbing Capacity of Deferred Taxes (“LACDT”)

The SCR has been adjusted for LACDT in the amount of US\$ 13,102,303 (2022: US\$ 9,632,269).

The Company has determined a level of probable future taxable profits aligned to its Own Risk and Solvency Assessment, which demonstrates future utilisation of the proportion of loss-absorbing capacity of deferred taxes being applied.

As a proportion of the instantaneous loss, as defined in Article 207(1), the Company’s LACDT represents 12.7% and as such is deemed not material.

E.3 Use of duration based equity risk Sub module in Solvency Capital Requirement calculation

The Company has not opted to use the duration-based equity risk sub-module set out in Article 304 of Directive 2009/138/EC.

E.4 Internal Model Information

The Company applies the Standard Formula model and does not use an internal model to calculate the Solvency Capital Requirement.

E.5 Non Compliance with Minimum Capital Requirement and Solvency Capital Requirement during the period

The Company was compliant at all times with the MCR and SCR requirements during the reporting period.

E.6 Any Other Information

Going Concern

In determining the appropriate basis of preparation of the annual financial statements, the Directors are required to consider whether the Company can continue in operational existence for at least 12 months from the date of approval of the financial statements ('the period of assessment'). The Directors are of the opinion that the going concern assumption is appropriate for the period of assessment based on the following considerations:

- (a) the Company's future business strategy,
- (b) the Company's future projected profitability;
- (c) the Company's liquidity position and the Company's capital position and the surplus over its required solvency capital requirement ("SCR") and minimum capital requirement ("MCR");
- (d) the financial position of the parent entity, Sasol Limited;

The Directors have reasonable expectations, having made appropriate enquiries that the Company has adequate resources to continue in operational existence for the foreseeable future. The Directors have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue. As a result, the Directors consider it appropriate to adopt the going concern basis in preparing these financial statements.

Sasol International Insurance DAC

Solvency and Financial Condition Report

Disclosures

30 June

2023

(Monetary amounts in USD thousands)

General information

Undertaking name	Sasol International Insurance DAC
Undertaking identification code	635400N4ZSEO8SUHF198
Type of code of undertaking	LEI
Type of undertaking	Non-life undertakings
Country of authorisation	IE
Language of reporting	en
Reporting reference date	30 June 2023
Currency used for reporting	USD
Accounting standards	Local GAAP
Method of Calculation of the SCR	Standard formula
Matching adjustment	No use of matching adjustment
Volatility adjustment	No use of volatility adjustment
Transitional measure on the risk-free interest rate	No use of transitional measure on the risk-free interest rate
Transitional measure on technical provisions	No use of transitional measure on technical provisions

List of reported templates

- S.02.01.02 - Balance sheet
- S.05.01.02 - Premiums, claims and expenses by line of business
- S.05.02.01 - Premiums, claims and expenses by country
- S.17.01.02 - Non-Life Technical Provisions
- S.19.01.21 - Non-Life insurance claims
- S.23.01.01 - Own Funds
- S.25.01.21 - Solvency Capital Requirement - for undertakings on Standard Formula
- S.28.01.01 - Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

S.02.01.02

Balance sheet

		Solvency II value
Assets		C0010
R0030	Intangible assets	0
R0040	Deferred tax assets	364
R0050	Pension benefit surplus	0
R0060	Property, plant & equipment held for own use	0
R0070	Investments (other than assets held for index-linked and unit-linked contracts)	248,555
R0080	<i>Property (other than for own use)</i>	0
R0090	<i>Holdings in related undertakings, including participations</i>	5
R0100	<i>Equities</i>	23,059
R0110	<i>Equities - listed</i>	23,059
R0120	<i>Equities - unlisted</i>	0
R0130	<i>Bonds</i>	19,132
R0140	<i>Government Bonds</i>	19,132
R0150	<i>Corporate Bonds</i>	0
R0160	<i>Structured notes</i>	0
R0170	<i>Collateralised securities</i>	0
R0180	<i>Collective Investments Undertakings</i>	7,755
R0190	<i>Derivatives</i>	0
R0200	<i>Deposits other than cash equivalents</i>	198,605
R0210	<i>Other investments</i>	0
R0220	Assets held for index-linked and unit-linked contracts	
R0230	Loans and mortgages	0
R0240	<i>Loans on policies</i>	0
R0250	<i>Loans and mortgages to individuals</i>	0
R0260	<i>Other loans and mortgages</i>	0
R0270	Reinsurance recoverables from:	41,336
R0280	<i>Non-life and health similar to non-life</i>	41,336
R0290	<i>Non-life excluding health</i>	41,336
R0300	<i>Health similar to non-life</i>	0
R0310	<i>Life and health similar to life, excluding index-linked and unit-linked</i>	0
R0320	<i>Health similar to life</i>	
R0330	<i>Life excluding health and index-linked and unit-linked</i>	
R0340	<i>Life index-linked and unit-linked</i>	
R0350	Deposits to cedants	0
R0360	Insurance and intermediaries receivables	483
R0370	Reinsurance receivables	11,880
R0380	Receivables (trade, not insurance)	0
R0390	Own shares (held directly)	0
R0400	Amounts due in respect of own fund items or initial fund called up but not yet paid in	0
R0410	Cash and cash equivalents	16,855
R0420	Any other assets, not elsewhere shown	3,118
R0500	Total assets	322,590

S.02.01.02

Balance sheet

		Solvency II value
Liabilities		C0010
R0510	Technical provisions - non-life	71,172
R0520	<i>Technical provisions - non-life (excluding health)</i>	70,979
R0530	<i>TP calculated as a whole</i>	0
R0540	<i>Best Estimate</i>	65,493
R0550	<i>Risk margin</i>	5,486
R0560	<i>Technical provisions - health (similar to non-life)</i>	193
R0570	<i>TP calculated as a whole</i>	0
R0580	<i>Best Estimate</i>	172
R0590	<i>Risk margin</i>	21
R0600	Technical provisions - life (excluding index-linked and unit-linked)	0
R0610	<i>Technical provisions - health (similar to life)</i>	0
R0620	<i>TP calculated as a whole</i>	
R0630	<i>Best Estimate</i>	
R0640	<i>Risk margin</i>	
R0650	<i>Technical provisions - life (excluding health and index-linked and unit-linked)</i>	0
R0660	<i>TP calculated as a whole</i>	
R0670	<i>Best Estimate</i>	
R0680	<i>Risk margin</i>	
R0690	Technical provisions - index-linked and unit-linked	0
R0700	<i>TP calculated as a whole</i>	
R0710	<i>Best Estimate</i>	
R0720	<i>Risk margin</i>	
R0740	Contingent liabilities	0
R0750	Provisions other than technical provisions	0
R0760	Pension benefit obligations	0
R0770	Deposits from reinsurers	0
R0780	Deferred tax liabilities	0
R0790	Derivatives	0
R0800	Debts owed to credit institutions	0
R0810	Financial liabilities other than debts owed to credit institutions	0
R0820	Insurance & intermediaries payables	462
R0830	Reinsurance payables	0
R0840	Payables (trade, not insurance)	0
R0850	Subordinated liabilities	0
R0860	<i>Subordinated liabilities not in BOF</i>	0
R0870	<i>Subordinated liabilities in BOF</i>	0
R0880	Any other liabilities, not elsewhere shown	369
R0900	Total liabilities	72,004
R1000	Excess of assets over liabilities	250,587

S.05.01.02

Premiums, claims and expenses by line of business

Non-life

Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)												Line of business for: accepted non-proportional reinsurance				Total	
Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Misc. financial loss	Health	Casualty	Marine, aviation and transport	Property		
C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0200	
0						44,742	15,610									60,352	
468						1,566										2,034	
																	0
0						30,185	2,049									32,235	
468						16,122	13,561									30,151	
0						44,742	15,610									60,352	
468						1,496										1,964	
																	0
0						30,185	2,049									32,235	
468						16,052	13,561									30,081	
						60,446	-794									59,653	
-4						-461										-465	
																	0
0						45,970	0									45,970	
-4						14,016	-794									13,218	
																0	
																0	
																	0
																0	
0						0	0									0	
4						820	335									1,159	
																1,159	

S.05.02.01
Premiums, claims and expenses by country

Non-life

R0010

Premiums written

R0110 Gross - Direct Business

R0120 Gross - Proportional reinsurance accepted

R0130 Gross - Non-proportional reinsurance accepted

R0140 Reinsurers' share

R0200 Net

Premiums earned

R0210 Gross - Direct Business

R0220 Gross - Proportional reinsurance accepted

R0230 Gross - Non-proportional reinsurance accepted

R0240 Reinsurers' share

R0300 Net

Claims incurred

R0310 Gross - Direct Business

R0320 Gross - Proportional reinsurance accepted

R0330 Gross - Non-proportional reinsurance accepted

R0340 Reinsurers' share

R0400 Net

Changes in other technical provisions

R0410 Gross - Direct Business

R0420 Gross - Proportional reinsurance accepted

R0430 Gross - Non-proportional reinsurance accepted

R0440 Reinsurers' share

R0500 Net

R0550 **Expenses incurred**

R1200 **Other expenses**

R1300 **Total expenses**

C0010	C0020	C0030	C0040	C0050	C0060	C0070
Home Country	Top 5 countries (by amount of gross premiums written) - non-life obligations			Top 5 countries (by amount of gross premiums written) - non-life obligations		Total Top 5 and home country
	ZA	US	IT	DE	MZ	
C0080	C0090	C0100	C0110	C0120	C0130	C0140
	49,507	8,929	658	1,257		60,352
	1,603				431	2,034
						0
	26,134	4,782	510	810		32,235
0	24,976	4,148	148	448	431	30,151
	49,507	8,929	658	1,257	0	60,352
	1,533				431	1,964
						0
	26,134	4,782	510	810		32,235
0	24,907	4,148	148	448	431	30,081
	3,699	56,433	-105	-374		59,653
	-465					-465
						0
		45,970				45,970
0	3,234	10,463	-105	-374	0	13,218
						0
						0
						0
0	0	0	0	0	0	0
	924	164	16	29	25	1,159
						1,159

S.17.01.02
Non-Life Technical Provisions

		Direct business and accepted proportional reinsurance											Accepted non-proportional reinsurance				Total Non-Life obligation	
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance		Non-proportional property reinsurance
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180
R0010	Technical provisions calculated as a whole																	0
R0050	Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole																	0
Technical provisions calculated as a sum of BE and RM																		
Best estimate																		
Premium provisions																		
R0060	Gross	0						0	0									0
R0140	Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	0						0	0									0
R0150	Net Best Estimate of Premium Provisions	0						0	0									0
Claims provisions																		
R0160	Gross	172						44,907	20,586									65,665
R0240	Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	0						30,583	10,752									41,336
R0250	Net Best Estimate of Claims Provisions	172						14,323	9,833									24,329
R0260	Total best estimate - gross	172						44,907	20,586									65,665
R0270	Total best estimate - net	172						14,324	9,833									24,329
R0280	Risk margin	21						1,589	3,898									5,507
Amount of the transitional on Technical Provisions																		
R0290	Technical Provisions calculated as a whole																	0
R0300	Best estimate																	0
R0310	Risk margin																	0
R0320	Technical provisions - total	193						46,496	24,484									71,172
R0330	Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - total	0						30,583	10,752									41,336
R0340	Technical provisions minus recoverables from reinsurance/SPV and Finite Re - total	193						15,912	13,731									29,836

S.19.01.21

Non-Life insurance claims

Total Non-life business

Z0020

Accident year / underwriting year

Underwriting Year

Gross Claims Paid (non-cumulative)	
2017	1,000
2018	1,000
2019	1,000
2020	1,000
2021	1,000
2022	1,000
2023	1,000
2024	1,000
2025	1,000
2026	1,000
2027	1,000
2028	1,000
2029	1,000
2030	1,000
2031	1,000
2032	1,000
2033	1,000
2034	1,000
2035	1,000
2036	1,000
2037	1,000
2038	1,000
2039	1,000
2040	1,000
2041	1,000
2042	1,000
2043	1,000
2044	1,000
2045	1,000
2046	1,000
2047	1,000
2048	1,000
2049	1,000
2050	1,000
2051	1,000
2052	1,000
2053	1,000
2054	1,000
2055	1,000
2056	1,000
2057	1,000
2058	1,000
2059	1,000
2060	1,000
2061	1,000
2062	1,000
2063	1,000
2064	1,000
2065	1,000
2066	1,000
2067	1,000
2068	1,000
2069	1,000
2070	1,000
2071	1,000
2072	1,000
2073	1,000
2074	1,000
2075	1,000
2076	1,000
2077	1,000
2078	1,000
2079	1,000
2080	1,000
2081	1,000
2082	1,000
2083	1,000
2084	1,000
2085	1,000
2086	1,000
2087	1,000
2088	1,000
2089	1,000
2090	1,000
2091	1,000
2092	1,000
2093	1,000
2094	1,000
2095	1,000
2096	1,000
2097	1,000
2098	1,000
2099	1,000
2100	1,000
2101	1,000
2102	1,000
2103	1,000
2104	1,000
2105	1,000
2106	1,000
2107	1,000
2108	1,000
2109	1,000
2110	1,000
2111	1,000
2112	1,000
2113	1,000
2114	1,000
2115	1,000
2116	1,000
2117	1,000
2118	1,000
2119	1,000
2120	1,000
2121	1,000
2122	1,000
2123	1,000
2124	1,000
2125	1,000
2126	1,000
2127	1,000
2128	1,000
2129	1,000
2130	1,000
2131	1,000
2132	1,000
2133	1,000
2134	1,000
2135	1,000
2136	1,000
2137	1,000
2138	1,000
2139	1,000
2140	1,000
2141	1,000
2142	1,000
2143	1,000
2144	1,000
2145	1,000
2146	1,000
2147	1,000
2148	1,000
2149	1,000
2150	1,000
2151	1,000
2152	1,000
2153	1,000
2154	1,000
2155	1,000
2156	1,000
2157	1,000
2158	1,000
2159	1,000
2160	1,000
2161	1,000

(absolute amount)

	Year	C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0170	C0180
		Development year										In Current year	Sum of years (cumulative)	
		0	1	2	3	4	5	6	7	8	9			10 & +
R0100	Prior											0	0	0
R0160	2013	0	0	0	0	0	0	0	0	0	0		0	0
R0170	2014	0	1,179	0	0	0	0	0	0	0			0	1,179
R0180	2015	0	0	0	0	0	0	0	0				0	0
R0190	2016	6,669	3,254	0	0	0	0	0					0	9,923
R0200	2017	0	0	0	0	0	0						0	0
R0210	2018	0	0	11	0	0							0	11
R0220	2019	0	1,305	0	0								0	1,305
R0230	2020	42,468	30,493	10,550									10,550	83,511
R0240	2021	6	4,436										4,436	4,441
R0250	2022	14,545											14,545	14,545
R0260												Total	29,530	114,916

Gross Undiscounted Best Estimate Claims Provisions

(absolute amount)

[illegible]

S.23.01.01
Own Funds

Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35

R0010	Ordinary share capital (gross of own shares)
R0030	Share premium account related to ordinary share capital
R0040	Initial funds, members' contributions or the equivalent basic own-fund item for mutual and mutual-type undertakings
R0050	Subordinated mutual member accounts
R0070	Surplus funds
R0090	Preference shares
R0110	Share premium account related to preference shares
R0130	Reconciliation reserve
R0140	Subordinated liabilities
R0160	An amount equal to the value of net deferred tax assets
R0180	Other own fund items approved by the supervisory authority as basic own funds not specified above

R0220 Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds

R0230 Deductions for participations in financial and credit institutions

R0290 Total basic own funds after deductions

Ancillary own funds

R0300	Unpaid and uncalled ordinary share capital callable on demand
R0310	Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand
R0320	Unpaid and uncalled preference shares callable on demand
R0330	A legally binding commitment to subscribe and pay for subordinated liabilities on demand
R0340	Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC
R0350	Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC
R0360	Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC
R0370	Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC
R0390	Other ancillary own funds
R0400	Total ancillary own funds

Available and eligible own funds

R0500	Total available own funds to meet the SCR
R0510	Total available own funds to meet the MCR
R0540	Total eligible own funds to meet the SCR
R0550	Total eligible own funds to meet the MCR

R0580	SCR
R0600	MCR
R0620	Ratio of Eligible own funds to SCR
R0640	Ratio of Eligible own funds to MCR

Reconcillation reserve

R0700	Excess of assets over liabilities
R0710	Own shares (held directly and indirectly)
R0720	Foreseeable dividends, distributions and charges
R0730	Other basic own fund items
R0740	Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds
R0760	Reconciliation reserve

Expected profits

R0770	Expected profits included in future premiums (EPIFP) - Life business
R0780	Expected profits included in future premiums (EPIFP) - Non- life business
R0790	Total Expected profits included in future premiums (EPIFP)

Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
C0010	C0020	C0030	C0040	C0050
624	624		0	
0	0		0	
0	0		0	
0		0	0	0
0	0			
0		0	0	0
0		0	0	0
249,599	249,599			
0		0	0	0
364				364
0	0	0	0	0
0				
0				
250,587	250,223	0	0	364

0		0	
0		0	
0		0	0
0		0	0
0		0	
0		0	0
0		0	
0		0	0
0		0	0
0		0	0

250,587	250,223	0	0	364
250,223	250,223	0	0	
250,587	250,223	0	0	364
250,223	250,223	0	0	

103,388
25,847
242.38%
968.10%

C0060
250,587
0
0
988
0
249,599

0

S.25.01.21

Solvency Capital Requirement - for undertakings on Standard Formula

R0010	Market risk
R0020	Counterparty default risk
R0030	Life underwriting risk
R0040	Health underwriting risk
R0050	Non-life underwriting risk
R0060	Diversification
R0070	Intangible asset risk
R0100	Basic Solvency Capital Requirement
Calculation of Solvency Capital Requirement	
R0130	Operational risk
R0140	Loss-absorbing capacity of technical provisions
R0150	Loss-absorbing capacity of deferred taxes
R0160	Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC
R0200	Solvency Capital Requirement excluding capital add-on
R0210	Capital add-ons already set
R0220	Solvency capital requirement
Other information on SCR	
R0400	Capital requirement for duration-based equity risk sub-module
R0410	Total amount of Notional Solvency Capital Requirements for remaining part
R0420	Total amount of Notional Solvency Capital Requirements for ring fenced funds
R0430	Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios
R0440	Diversification effects due to RFF nSCR aggregation for article 304

Approach to tax rate

R0590	Approach based on average tax rate
-------	------------------------------------

Calculation of loss absorbing capacity of deferred taxes

R0640	LAC DT
R0650	LAC DT justified by reversion of deferred tax liabilities
R0660	LAC DT justified by reference to probable future taxable economic profit
R0670	LAC DT justified by carry back, current year
R0680	LAC DT justified by carry back, future years
R0690	Maximum LAC DT

Gross solvency capital requirement	USP	Simplifications
C0110	C0090	C0120
43,357		
17,682		
0		
20,022		
79,891		
-46,432		
0		
114,520		
C0100		
1,970		
0		
-13,102		
0		
103,388		
0		
103,388		
0		
0		
0		
0		
0		
C0109		
Yes		
LAC DT		
C0130		
-13,102		
0		
-13,102		
0		
0		
0		

USP Key

For life underwriting risk:
1 - Increase in the amount of annuity benefits
9 - None

For health underwriting risk:
1 - Increase in the amount of annuity benefits
2 - Standard deviation for NSLT health premium risk
3 - Standard deviation for NSLT health gross premium risk
4 - Adjustment factor for non-proportional reinsurance
5 - Standard deviation for NSLT health reserve risk
9 - None

For non-life underwriting risk:
4 - Adjustment factor for non-proportional reinsurance
6 - Standard deviation for non-life premium risk
7 - Standard deviation for non-life gross premium risk
8 - Standard deviation for non-life reserve risk
9 - None

Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Linear formula component for non-life insurance and reinsurance obligations

R0010 MCR_{NL} Result

C0010

5,375

Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
---	---

C0020

C0030

[illegible]

Linear formula component for life insurance and reinsurance obligations

R0200 MCR_L Result

C0040

0

Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
---	--

C0050

C0060

Overall MCR calculation

C0070

R0300	Linear MCR	5,375
R0310	SCR	103,388
R0320	MCR cap	46,524
R0330	MCR floor	25,847
R0340	Combined MCR	25,847
R0350	Absolute floor of the MCR	4,346
R0400	Minimum Capital Requirement	25,847